Literature DB >> 12634350

Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication.

Chunfu Wang1, Jill Pflugheber, Rhea Sumpter, Donald L Sodora, Daniel Hui, Ganes C Sen, Michael Gale.   

Abstract

Hepatitis C virus (HCV) infection is treated with interferon (IFN)-based therapy. The mechanisms by which IFN suppresses HCV replication are not known, and only limited efficacy is achieved with therapy because the virus directs mechanisms to resist the host IFN response. In the present study we characterized the effects of IFN action upon the replication of two distinct quasispecies of an HCV replicon whose encoded NS5A protein exhibited differential abilities to bind and inhibit protein kinase R (PKR). Metabolic labeling experiments revealed that IFN had little overall effect upon HCV protein stability or polyprotein processing but specifically blocked translation of the HCV RNA, such that the replication of both viral quasispecies was suppressed by IFN treatment of the Huh7 host cells. However, within cells expressing an NS5A variant that inhibited PKR, we observed a reduced level of eukaryotic initiation factor 2 alpha subunit (eIF2alpha) phosphorylation and a concomitant increase in HCV protein synthetic rates, enhancement of viral RNA replication, and a partial rescue of viral internal ribosome entry site (IRES) function from IFN suppression. Assessment of the ribosome distribution of the HCV replicon RNA demonstrated that the NS5A-mediated block in eIF2alpha phosphorylation resulted in enhanced recruitment of the HCV RNA into polyribosome complexes in vivo but only partially rescued the RNA from polyribosome dissociation induced by IFN treatment. Examination of cellular proteins associated with HCV-translation complexes in IFN-treated cells identified the P56 protein as an eIF3-associated factor that fractionated with the initiator ribosome-HCV RNA complex. Importantly, we found that P56 could independently suppress HCV IRES function both in vitro and in vivo, but a mutant P56 that was unable to bind eIF3 had no suppressive action. We conclude that IFN blocks HCV replication through translational control programs involving PKR and P56 to, respectively, target eIF2- and eIF3-dependent steps in the viral RNA translation initiation process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634350      PMCID: PMC150642          DOI: 10.1128/jvi.77.7.3898-3912.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

Review 2.  The double-stranded RNA-dependent protein kinase PKR: structure and function.

Authors:  M J Clemens; A Elia
Journal:  J Interferon Cytokine Res       Date:  1997-09       Impact factor: 2.607

3.  What happens inside lentivirus or influenza virus infected cells: insights into regulation of cellular and viral protein synthesis.

Authors:  M Gale; M G Katze
Journal:  Methods       Date:  1997-04       Impact factor: 3.608

Review 4.  Epidemiology of hepatitis C.

Authors:  M J Alter
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 5.  Therapy of hepatitis C: overview.

Authors:  K L Lindsay
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 6.  Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase.

Authors:  M Gale; M G Katze
Journal:  Pharmacol Ther       Date:  1998-04       Impact factor: 12.310

7.  Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2alpha.

Authors:  M Kawagishi-Kobayashi; J B Silverman; T L Ung; T E Dever
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

8.  Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs.

Authors:  D V Sizova; V G Kolupaeva; T V Pestova; I N Shatsky; C U Hellen
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

9.  Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase.

Authors:  K E Reed; J Xu; C M Rice
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

10.  Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation.

Authors:  M Gale; C M Blakely; B Kwieciszewski; S L Tan; M Dossett; N M Tang; M J Korth; S J Polyak; D R Gretch; M G Katze
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more
  95 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication.

Authors:  Paramananda Saikia; Volker Fensterl; Ganes C Sen
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections.

Authors:  Dong Jiang; Jessica M Weidner; Min Qing; Xiao-Ben Pan; Haitao Guo; Chunxiao Xu; Xianchao Zhang; Alex Birk; Jinhong Chang; Pei-Yong Shi; Timothy M Block; Ju-Tao Guo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

4.  Inhibitor of κB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection.

Authors:  Olivia Perwitasari; Hyelim Cho; Michael S Diamond; Michael Gale
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 5.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 6.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

7.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.

Authors:  Eileen Foy; Kui Li; Rhea Sumpter; Yueh-Ming Loo; Cynthia L Johnson; Chunfu Wang; Penny Mar Fish; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

8.  The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.

Authors:  Eleanor N Fish; Stephen A Harrison; Tarek Hassanein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-09

Review 9.  Interaction of hepatitis C virus with the type I interferon system.

Authors:  Friedemann Weber
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS + RT).

Authors:  Hasan H Danish; Sharad Goyal; Neil K Taunk; Hao Wu; Meena S Moran; Bruce G Haffty
Journal:  Breast J       Date:  2013-03-26       Impact factor: 2.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.